2/25
08:00 am
grce
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
High
Report
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
2/18
08:00 am
grce
Grace Therapeutics, Inc. (NASDAQ: GRCE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Grace Therapeutics, Inc. (NASDAQ: GRCE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
2/13
09:40 am
grce
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update [Yahoo! Finance]
Low
Report
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update [Yahoo! Finance]
2/13
08:00 am
grce
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Neutral
Report
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
2/11
10:32 am
grce
Grace Therapeutics secures $15m for GTx-104 pre-commercial development [Yahoo! Finance]
Medium
Report
Grace Therapeutics secures $15m for GTx-104 pre-commercial development [Yahoo! Finance]
2/10
09:32 am
grce
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH [Yahoo! Finance]
Medium
Report
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH [Yahoo! Finance]
2/10
08:05 am
grce
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
High
Report
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
2/10
08:01 am
grce
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Low
Report
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
1/7
08:00 am
grce
Grace Therapeutics to Participate in Upcoming Investor Events January 2025
Low
Report
Grace Therapeutics to Participate in Upcoming Investor Events January 2025